Positive Topline Efficacy Results for the Phase 2b QUALITY Clinical Study: Enobosarm in Combination with GLP-1 RA Drugs Makes Weight Reduction More ... and hemoglobin A1c at 24 weeks.

Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Key Takeaways Real-world results with weight-loss drugs aren’t as impressive as those in clinical trialsClinic patients ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

The number of people prescribed GLP-1 drugs for weight management has skyrocketed over the past five years, according to new data from FAIR Health. The report found that just over 2% of adults in ...

Semaglutide medications work by increasing the levels of a hormone called GLP-1 (glucagon-like peptide 1), a satiety signal that slows digestion and makes us feel full. These drugs also ...

Get Instant Summarized Text (Gist) In adults with diabetes and obesity, use of GLP-1 receptor agonists is associated with a modestly lower risk of obesity-related cancers and all-cause mortality ...

Obesity prevalence is rising, with GLP-1 receptor agonists offering promising treatment options, yet access is limited by high costs and insurance restrictions. A study from 2021 to 2024 showed ...

“New generation, highly potent GLP-1 [drugs] with higher efficacy in weight reduction may convey an even greater advantage in reducing the risk of obesity-related cancers, but future research is ...